Literature DB >> 21649528

Switching therapy from variable-dose multiple pill to fixed-dose single-pill combinations of angiotensin II receptor blockers and thiazides for hypertension.

Atsushi Sakima1, Katsuhiko Ohshiro, Seigo Nakada, Masanobu Yamazato, Kentaro Kohagura, Minori Nakamoto, Takeshi Tana, Yusuke Ohya.   

Abstract

The efficacy and tolerability of switching therapy from free combinations of angiotensin II receptor blocker (ARB) and thiazide (A/T) to a fixed-dose of losartan and hydrochlorothiazide (L/H) has not been evaluated in Japan. We examined effects of switching therapy from variable-dose multiple-pill A/T to a fixed-dose L/H on blood pressure (BP) along with medication adherence and the degree of satisfaction in 91 hypertensive outpatients (mean age, 65.2 ± 9.6 years). After 6 months, a significant BP reduction (132 ± 9/76 ± 10 vs. 126 ± 12/72 ± 11 mm Hg), along with an improvement of attaining target BP (44.0 vs. 61.5%) and that of adherence, were observed. The magnitude of BP reduction in the participants increased their degree of satisfaction more significantly than in the participants who worsened their degree of satisfaction. The estimated glomerular filtration rate and the serum uric acid (UA) level decreased slightly but significantly. The hemoglobin A1c of participants with diabetes mellitus increased slightly but significantly. In conclusion, a switch in therapy from variable-dose, multiple-pill A/T combinations to a fixed-dose, single-pill L/H was effective in decreasing BP and serum UA in Japanese clinical practice. Metabolic side effects of L/H in patients with diabetes mellitus remain to be investigated.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21649528     DOI: 10.3109/10641963.2010.549260

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  4 in total

1.  Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg.

Authors:  Hiromi Rakugi; Takuya Tsuchihashi; Kazuyuki Shimada; Hirotaka Numaguchi; Chisato Nishida; Hiroya Yamaguchi; Masayoshi Shirakawa; Kyoichi Azuma; Kenji P Fujita
Journal:  Hypertens Res       Date:  2015-02-26       Impact factor: 3.872

2.  Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of fimasartan, amlodipine, and rosuvastatin using partial replicated design in healthy adult subjects.

Authors:  Minkyung Oh; Jong-Lyul Ghim; Sung-Eun Park; Eun-Young Kim; Jae-Gook Shin
Journal:  Drug Des Devel Ther       Date:  2018-05-08       Impact factor: 4.162

3.  Economic impact of switching to fixed-dose combination therapy for Japanese hypertensive patients: a retrospective cost analysis.

Authors:  Manabu Akazawa; Katsushi Fukuoka
Journal:  BMC Health Serv Res       Date:  2013-04-03       Impact factor: 2.655

4.  Pharmacokinetic comparison between fixed-dose combination of fimasartan/amlodipine 60/10 mg and the corresponding loose combination through partial replicated crossover study in healthy subjects.

Authors:  Eunsol Yang; Soyoung Lee; Heechan Lee; Inyoung Hwang; In-Jin Jang; Kyung-Sang Yu; SeungHwan Lee
Journal:  Transl Clin Pharmacol       Date:  2019-12-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.